Insider Selling: BioDelivery Sciences International, Inc. (BDSI) Director Sells 108,000 Shares of Stock

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Mark A. Sirgo sold 108,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $2.57, for a total transaction of $277,560.00. Following the transaction, the director now directly owns 1,759,262 shares in the company, valued at $4,521,303.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of BioDelivery Sciences International, Inc. (BDSI) traded up $0.12 during trading hours on Friday, reaching $2.70. 532,970 shares of the company were exchanged, compared to its average volume of 599,860. The company has a market capitalization of $150.89, a PE ratio of 30.00 and a beta of 0.74. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.28 and a quick ratio of 1.07. BioDelivery Sciences International, Inc. has a fifty-two week low of $1.55 and a fifty-two week high of $3.60.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. The business had revenue of $11.25 million for the quarter, compared to analysts’ expectations of $9.40 million. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. The firm’s quarterly revenue was up 215.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.30) earnings per share. sell-side analysts predict that BioDelivery Sciences International, Inc. will post 0.16 EPS for the current fiscal year.

Several research analysts have recently commented on BDSI shares. HC Wainwright set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Monday, November 27th. Roth Capital set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Monday, November 13th. Piper Jaffray Companies set a $4.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Sunday, October 22nd. Finally, Cantor Fitzgerald set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Thursday, October 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $4.29.

Large investors have recently made changes to their positions in the stock. Advisor Group Inc. increased its stake in BioDelivery Sciences International by 42.1% in the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after acquiring an additional 13,341 shares during the last quarter. Royce & Associates LP bought a new position in BioDelivery Sciences International in the third quarter valued at approximately $3,814,000. Stonepine Capital Management LLC increased its stake in BioDelivery Sciences International by 22.2% in the second quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock valued at $9,737,000 after acquiring an additional 632,853 shares during the last quarter. GSA Capital Partners LLP increased its stake in BioDelivery Sciences International by 10.1% in the second quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock valued at $1,369,000 after acquiring an additional 44,700 shares during the last quarter. Finally, EAM Investors LLC increased its stake in BioDelivery Sciences International by 62.1% in the third quarter. EAM Investors LLC now owns 780,635 shares of the specialty pharmaceutical company’s stock valued at $2,303,000 after acquiring an additional 299,163 shares during the last quarter. 44.08% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: BioDelivery Sciences International, Inc. (BDSI) Director Sells 108,000 Shares of Stock” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/19/insider-selling-biodelivery-sciences-international-inc-bdsi-director-sells-108000-shares-of-stock.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply